Navigation Links
OncoGenex Pharmaceuticals to Host Investor Conference Call at 8:30 a.m. ET, December 21, 2009
Date:12/20/2009

BOTHELL, WA and VANCOUVER, BC, Dec. 20 /PRNewswire-FirstCall/ - OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today that the Company will host a conference call at 8:30 a.m. Eastern Time on Monday, December 21, 2009.

A live webcast will be available through the Investor Relations page of the OncoGenex Web site at http://ir.oncogenex.com. Alternatively, you may access the live conference call by dialing 888-747-4649 (U.S. & Canada) or 913-312-1507 (International). A webcast replay will be available approximately two hours after the call and will be archived on www.oncogenex.com for 90 days.

About OncoGenex Pharmaceuticals

OncoGenex is a biopharmaceutical company committed to the development and commercialization of new cancer therapies that address treatment resistance in cancer patients. OncoGenex has a deep oncology pipeline, with each product candidate having a distinct mechanism of action and representing a unique opportunity for cancer drug development. OGX-011, the lead candidate that has completed five Phase II clinical trials in prostate, lung and breast cancers, is designed to inhibit the production of a specific protein associated with treatment resistance; OGX-427 is in Phase I clinical development; SN2310 has completed a Phase I clinical trial; and CSP-9222 and OGX-225 are currently in pre-clinical development. More information about OncoGenex is available at www.oncogenex.com.

SOURCE OncoGenex Pharmaceuticals, Inc.


'/>"/>
SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. OncoGenex Reports Third Quarter 2009 Financial Results
2. OncoGenex Pharmaceuticals to Release Third Quarter 2009 Financial Results
3. OncoGenex Pharmaceuticals CEO Named Canadas Pacific Ernst & Youngs Entrepreneur Of The Year(R) in the Health Sciences Category
4. OncoGenex Pharmaceuticals to Webcast Presentations at September Investor Conferences
5. OncoGenex Pharmaceuticals Announces Issuance of Key Patent for OGX-011
6. OncoGenex Reports Second Quarter 2009 Financial Results
7. OncoGenex Pharmaceuticals to Release Second Quarter 2009 Financial Results
8. OncoGenex Pharmaceuticals Completes $9.5 Million Registered Direct Offering
9. OncoGenex Pharmaceuticals to Raise $9.5 Million Through Sale of Common Stock
10. OncoGenex Pharmaceuticals Added to Russell Indexes
11. OncoGenex Pharmaceuticals Files Shelf Registration Statement
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/22/2017)... Maryland (PRWEB) , ... March 21, 2017 , ... ... Life Science Chief Executive Officer Forum on March 23-24 in San Diego. The ... medical device and diagnostic industries. , Benchworks Vice President Christian Meyer will also ...
(Date:3/22/2017)... Washington, USA, and CARDIFF, UK (PRWEB) , ... March 21, 2017 ... ... regional blood flow and tissue oxygenation, is being explored as a way to track ... near-infrared spectroscopy study on tonic pain activation by cold pressor test ,” published today ...
(Date:3/22/2017)... -- Personal Genome Diagnostics Inc. (PGDx) today announced an ... U.S. Department of Veterans Affairs (VA) that replaces ... new CancerSELECT ™ 125 test. CancerSELECT 125 ... that includes microsatellite instability status (MSI), a biomarker ... inhibitor immunotherapies. CancerSELECT 125 will be available to ...
(Date:3/20/2017)... ... March 20, 2017 , ... ... with the ability of endogenous hormones to regulate homeostasis via their cognate ... (antagonists), EDCs produce adverse reproductive, neurological, proliferative, and immunological disorders. EDC exposure ...
Breaking Biology Technology:
(Date:3/20/2017)... At this year,s CeBIT Chancellor Dr. Angela Merkel ... came to the DERMALOG stand together with the Japanese Prime Minster Shinzo ... At the largest German biometrics company the two government leaders could see ... as well as DERMALOG´s multi-biometrics system.   Continue ... ...
(Date:3/9/2017)... SAN FRANCISCO and MOUNTAIN VIEW, ... Zipongo , "Eating Well Made Simple," and 23andMe ... to help guide better food choices.  Zipongo can now ... only their food preferences, health goals and biometrics, but ... to certain food choices. Zipongo,s personalized food ...
(Date:3/2/2017)... , March 2, 2017 Summary ... better understand Merck KGaA and its partnering interests and ... https://www.reportbuyer.com/product/3605601/ Description The Partnering Deals and Alliance ... partnering activity of one of the world,s leading life ... prepared upon purchase to ensure inclusion of the most ...
Breaking Biology News(10 mins):